Header Logo

Connection

Yehuda Handelsman to Hypoglycemic Agents

Back to Details
This is a "connection" page, showing publications Yehuda Handelsman has written about Hypoglycemic Agents.
Yehuda Handelsman
Connection Strength
10.940
Hypoglycemic Agents
  1. Paradigm shift in the management of DM & CVD-preventing the next CV event. J Diabetes. 2020 Sep; 12(9):630-632.
    View in: PubMed
    Score: 0.604
  2. Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine. Adv Ther. 2019 12; 36(12):3321-3339.
    View in: PubMed
    Score: 0.569
  3. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes. Adv Ther. 2019 10; 36(10):2567-2586.
    View in: PubMed
    Score: 0.562
  4. Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab. 2019 04; 21(4):883-892.
    View in: PubMed
    Score: 0.538
  5. Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes. J Diabetes Complications. 2019 03; 33(3):236-242.
    View in: PubMed
    Score: 0.535
  6. Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists. J Manag Care Spec Pharm. 2018 Sep; 24(9-a Suppl):S14-S29.
    View in: PubMed
    Score: 0.525
  7. A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Curr Med Res Opin. 2017 10; 33(10):1861-1868.
    View in: PubMed
    Score: 0.484
  8. Diabetes treatment over age 65: Is worse control really better? J Diabetes. 2017 May; 9(5):428-430.
    View in: PubMed
    Score: 0.473
  9. Approaches to treatment 2: Comparison of American Association of Clinical Endocrinologists (AACE) and American Diabetes Association (ADA) type 2 diabetes treatment guidelines. J Diabetes. 2016 Jan; 8(1):4-6.
    View in: PubMed
    Score: 0.434
  10. SGLT-2 INHIBITION ADDED TO GLP-1 AGONIST THERAPY FOR TYPE 2 DIABETES: WHAT IS THE BENEFIT? Endocr Pract. 2015 Dec; 21(12):1442-4.
    View in: PubMed
    Score: 0.431
  11. POTENTIAL PLACE OF SGLT2 INHIBITORS IN TREATMENT PARADIGMS FOR TYPE 2 DIABETES MELLITUS. Endocr Pract. 2015 Sep; 21(9):1054-65.
    View in: PubMed
    Score: 0.422
  12. Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study. Diabetes Care. 2014 Oct; 37(10):2723-30.
    View in: PubMed
    Score: 0.395
  13. Lessons from glargine trials: what is the goal fasting glucose with basal insulin? J Diabetes. 2014 Jul; 6(4):271-3.
    View in: PubMed
    Score: 0.388
  14. Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: a meta-analysis of 5 randomized begin trials. Endocr Pract. 2014 Apr; 20(4):285-92.
    View in: PubMed
    Score: 0.387
  15. The Avandia debate: an unhappy conclusion. J Diabetes. 2010 Dec; 2(4):221-2.
    View in: PubMed
    Score: 0.307
  16. Cancer mortality and insulin glargine. J Diabetes. 2009 Sep; 1(3):131-3.
    View in: PubMed
    Score: 0.278
  17. Pharmacologic treatment options for prediabetes. Nat Clin Pract Endocrinol Metab. 2008 Jul; 4(7):380-1.
    View in: PubMed
    Score: 0.258
  18. Treating diabetes with incretin hormones - clinical experience. Pediatr Endocrinol Rev. 2008 Jun; 5(4):897-903.
    View in: PubMed
    Score: 0.258
  19. Intense simplified strategy for newly diagnosed type 2 diabetes in patients with severe hyperglycaemia: multicentre, open label, randomised trial. BMJ. 2024 10 15; 387:e080122.
    View in: PubMed
    Score: 0.201
  20. Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Glargine (Gan & Lee Glargine) Compared With Originator Insulin Glargine (Lantus) in Patients With Type 1 Diabetes After 26?Weeks Treatment. Endocr Pract. 2024 Sep; 30(9):810-816.
    View in: PubMed
    Score: 0.196
  21. DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. J Diabetes Complications. 2022 02; 36(2):108101.
    View in: PubMed
    Score: 0.165
  22. Sodium-glucose cotransporter 2 inhibitors for macroalbuminuria: A new indication. J Diabetes. 2020 Jan; 12(1):8-9.
    View in: PubMed
    Score: 0.143
  23. Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications. J Manag Care Spec Pharm. 2018 Sep; 24(9-a Suppl):S42-S52.
    View in: PubMed
    Score: 0.131
  24. Health-Related Quality of Life Assessments with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus. J Manag Care Spec Pharm. 2018 Sep; 24(9-a Suppl):S30-S41.
    View in: PubMed
    Score: 0.131
  25. Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100?U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes. Diabetes Obes Metab. 2018 12; 20(12):2821-2829.
    View in: PubMed
    Score: 0.131
  26. American College of Physicians diabetes guidelines attempt to turn back the clock, conflating good HbA1c with hypoglycemia. J Diabetes. 2018 Aug; 10(8):618-620.
    View in: PubMed
    Score: 0.128
  27. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY. Endocr Pract. 2018 01; 24(1):91-120.
    View in: PubMed
    Score: 0.126
  28. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial. JAMA. 2017 Jul 04; 318(1):45-56.
    View in: PubMed
    Score: 0.121
  29. Lorcaserin treatment allows for decreased number needed to treat for weight and glycemic parameters in week 12 responders with =5% weight loss. Postgrad Med. 2016 Nov; 128(8):740-746.
    View in: PubMed
    Score: 0.115
  30. PATIENTS ACHIEVING GOOD GLYCEMIC CONTROL (HBA1c <7%) EXPERIENCE A LOWER RATE OF HYPOGLYCEMIA WITH INSULIN DEGLUDEC THAN WITH INSULIN GLARGINE: A META-ANALYSIS OF PHASE 3A TRIALS. Endocr Pract. 2015 Aug; 21(8):917-26.
    View in: PubMed
    Score: 0.105
  31. Health status and hypoglycaemia with insulin degludec versus insulin glargine: a 2-year trial in insulin-na?ve patients with type 2 diabetes. Diabetes Obes Metab. 2014 Sep; 16(9):869-72.
    View in: PubMed
    Score: 0.096
  32. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON). Diabetes Obes Metab. 2014 Jul; 16(7):636-44.
    View in: PubMed
    Score: 0.096
  33. Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type?2 diabetes: a 2-year randomized, treat-to-target trial. Diabet Med. 2013 Nov; 30(11):1298-304.
    View in: PubMed
    Score: 0.093
  34. Diabetes and cancer--an AACE/ACE consensus statement. Endocr Pract. 2013 Jul-Aug; 19(4):675-93.
    View in: PubMed
    Score: 0.092
  35. The role of bromocriptine-QR in the management of type 2 diabetes expert panel recommendations. Endocr Pract. 2013 Jan-Feb; 19(1):100-6.
    View in: PubMed
    Score: 0.089
  36. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 2012 Dec; 35(12):2464-71.
    View in: PubMed
    Score: 0.087
  37. Initial combination therapy with metformin plus colesevelam in drug-na?ve Hispanic patients with early type 2 diabetes. Postgrad Med. 2012 Jul; 124(4):7-13.
    View in: PubMed
    Score: 0.086
  38. Diabetes in youth: a dilemma of pathogenesis. J Diabetes. 2011 Jun; 3(2):91-2.
    View in: PubMed
    Score: 0.079
  39. Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes. Endocr Pract. 2010 Jul-Aug; 16(4):629-40.
    View in: PubMed
    Score: 0.075
  40. Insulin treatment of Type 2 diabetes: a clinical perspective. J Diabetes. 2010 Jun; 2(2):65-6.
    View in: PubMed
    Score: 0.073
  41. Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy. Endocr Pract. 2010 Jan-Feb; 16(1):53-63.
    View in: PubMed
    Score: 0.072
  42. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009 Sep-Oct; 15(6):540-59.
    View in: PubMed
    Score: 0.070
  43. Hypoglycemia in the intensive care unit. Curr Opin Clin Nutr Metab Care. 2007 Mar; 10(2):193-6.
    View in: PubMed
    Score: 0.059
  44. Cardio-renal-metabolic disease in primary care setting. Diabetes Metab Res Rev. 2024 Mar; 40(3):e3755.
    View in: PubMed
    Score: 0.047
  45. EFFICACY AND SAFETY OF IDEGLIRA IN OLDER PATIENTS WITH TYPE 2 DIABETES. Endocr Pract. 2019 Feb; 25(2):144-155.
    View in: PubMed
    Score: 0.033
  46. Burden of Illness in Type 2 Diabetes Mellitus. J Manag Care Spec Pharm. 2018 Sep; 24(9-a Suppl):S5-S13.
    View in: PubMed
    Score: 0.033
  47. Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. Diabetes. 2017 02; 66(2):241-255.
    View in: PubMed
    Score: 0.029
  48. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY 2016 OUTPATIENT GLUCOSE MONITORING CONSENSUS STATEMENT. Endocr Pract. 2016 Feb; 22(2):231-61.
    View in: PubMed
    Score: 0.027
  49. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. Endocr Pract. 2016 Jan; 22(1):84-113.
    View in: PubMed
    Score: 0.027
  50. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2015 EXECUTIVE SUMMARY. Endocr Pract. 2015 Dec; 21(12):1403-14.
    View in: PubMed
    Score: 0.027
  51. Proceedings from the American Association of Clinical Endocrinologists and American College of Endocrinology consensus conference on glucose monitoring. Endocr Pract. 2015 May; 21(5):522-33.
    View in: PubMed
    Score: 0.026
  52. American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary. Endocr Pract. 2013 May-Jun; 19(3):536-57.
    View in: PubMed
    Score: 0.023
  53. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013 Mar-Apr; 19(2):327-36.
    View in: PubMed
    Score: 0.022
  54. Statement by the American Association of Clinical Endocrinologists Consensus Panel on insulin pump management. Endocr Pract. 2010 Sep-Oct; 16(5):746-62.
    View in: PubMed
    Score: 0.019
  55. Road maps to achieve glycemic control in type 2 diabetes mellitus: ACE/AACE Diabetes Road Map Task Force. Endocr Pract. 2007 May-Jun; 13(3):260-8.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.